Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan.
In Vivo. 2022 Mar-Apr;36(2):979-984. doi: 10.21873/invivo.12790.
BACKGROUND/AIM: Surgery remains the standard treatment for salivary gland carcinoma (SGC). Our study investigated the association between epidermal growth factor receptor (EGFR) status in recurrent/metastatic SGC and the effectiveness of treatment with cisplatin/carboplatin and 5-fluorouracil plus cetuximab (EXTREME).
We retrospectively collected 19 SGCs from patients treated with the EXTREME regimen. After analyzing EGFR expression and gene copy number gain, we evaluated the correlation between EGFR status and clinicopathological factors and prognosis.
EGFR overexpression was detected in 77.8% cases, but not statistically associated with clinicopathological factors or prognosis. EGFR gene copy number gain was detected in 16.7% cases, and statistically positively correlated with lymph node metastasis (p=0.0291). The best overall response was partial response in two cases, stable disease in 15, and progressive disease in one case. The EXTREME regimen was discontinued in all cases.
Our results suggest that SGCs are positive for EGFR protein expression but the response rate to the EXTREME regimen was unremarkable.
背景/目的：手术仍然是治疗唾液腺癌（SGC）的标准治疗方法。我们的研究调查了复发性/转移性 SGC 中表皮生长因子受体（EGFR）状态与顺铂/卡铂和 5-氟尿嘧啶联合西妥昔单抗（EXTREME）治疗效果之间的关联。
我们回顾性地从接受 EXTREME 方案治疗的患者中收集了 19 例 SGC。在分析 EGFR 表达和基因拷贝数增加后，我们评估了 EGFR 状态与临床病理因素和预后之间的相关性。
77.8%的病例检测到 EGFR 过表达，但与临床病理因素或预后无统计学关联。16.7%的病例检测到 EGFR 基因拷贝数增加，与淋巴结转移呈统计学正相关（p=0.0291）。最佳总体反应为两例部分缓解，15 例稳定疾病，一例进展性疾病。所有病例均停止使用 EXTREME 方案。
我们的结果表明，SGC 中 EGFR 蛋白表达阳性，但 EXTREME 方案的反应率并不显著。
